KOSDAQ - Delayed Quote KRW

009420.KQ,0P0000BTQO,343544 (009420.KQ)

36,300.00

+300.00

+(0.83%)

At close: July 20 at 5:00:00 AM GMT+9

HanAll Biopharma Announces Orphan Drug Designation for Batoclimab in Japan for Active Thyroid Eye Disease

HanAll Biopharma Co., Ltd. (KRX: 009420.KS), a global biopharmaceutical company committed to discovering and developing innovative medicines for patients, announced that Batoclimab, an anti-FcRn treatment being developed for a range of autoimmune diseases, has received Orphan Drug Designation (ODD) from the Ministry of Health, Labor and Welfare (MHLW) in Japan for active Thyroid Eye Disease (TED).

PR Newswire last month

009420.KQ
+0.83%

009420.KS
HanAll Biopharma, Daewoong Pharmaceutical and NurrOn Pharmaceuticals Announce Successful Completion of a First-in-Human Study for Potential Disease-Modifying Therapy for Parkinson's Disease

HanAll Biopharma, Daewoong Pharmaceutical and NurrOn Pharmaceuticals successfully completed their Phase 1 study of HL192 (ATH-399A), which is being developed as a disease-modifying therapy for Parkinson's disease. The study met its primary endpoints of safety and tolerability in 5 different ascending dose groups, demonstrating significant progress in the treatment of this debilitating neurological disorder. This first-in-human study included single ascending dose (SAD), multiple ascending dose (

PR Newswire 5 months ago

009420.KQ
+0.83%

009420.KS
HanAll Biopharma Reports Q3 2024 Financial Results and Provides Business Update

HanAll Biopharma Co., Ltd. (KRX: 009420.KS), a global biopharmaceutical company committed to discovering and developing innovative medicines for patients, reported financial results for the third quarter of 2024 and provided business updates.

PR Newswire 5 months ago

009420.KQ
+0.83%

009420.KS
HanAll Biopharma Reports Q2 2024 Financial Results and Provides Business Update

HanAll Biopharma Co., Ltd. (KRX: 009420.KS), a global biopharmaceutical company committed to discovering and developing innovative medicines for patients, reported financial results for the second quarter of 2024 and provided business updates.

PR Newswire 9 months ago

009420.KQ
+0.83%

009420.KS
HanAll Biopharma Appoints Christopher W Slavinsky as Chief Business Development and Legal Officer

HanAll Biopharma (KRX: 009420.KS) announced today the appointment of Christopher W. Slavinsky as Chief Business Development and Legal Officer.

PR Newswire 9 months ago

009420.KQ
+0.83%

009420.KS

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

009420.KQ,0P0000BTQO,343544 (009420.KQ)

HanAll Biopharma Announces Orphan Drug Designation for Batoclimab in Japan for Active Thyroid Eye Disease

HanAll Biopharma, Daewoong Pharmaceutical and NurrOn Pharmaceuticals Announce Successful Completion of a First-in-Human Study for Potential Disease-Modifying Therapy for Parkinson's Disease

HanAll Biopharma Reports Q3 2024 Financial Results and Provides Business Update

HanAll Biopharma Reports Q2 2024 Financial Results and Provides Business Update

HanAll Biopharma Appoints Christopher W Slavinsky as Chief Business Development and Legal Officer